R. P. Melinkeri
5 Papers
R. P. Melinkeri is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2
S S Iyengar,Raman Puri,S. N. Narasingan,Devaki Nair,Vimal Mehta,Jagdish C. Mohan,Subhash Kumar Wangnoo,J. J. Dalal,V. Jha,S. Puri,Anoop Misra,Mradul Kumar Daga,M. S. K. Varma,Sanjiv Jasuja,S. D. Upadhyaya,Ravi R Kasliwal,Manish Bansal,Rahul Mehrotra,A. Jain,Kewal K. Talwar,Rajesh Rajput,Akshyaya Pradhan,Shashi Seth,Dheeraj Kapoor,R. P. Melinkeri,Sivasubramanian Ramakrishnan,Narendra N. Khanna,Rajesh Khadgawat,Altamash Shaikh,N. Kovalipati,N. Bordoloi,Abdul Hamid Zargar,Rajeev Agarwal,Ashu Rastogi,M. Chag,D Prabhakar,S. K. Mathur,Harmeet Singh Rehan,P. K. Sahoo,A.L. Dutta,A. D. Sharma,A. K. Pancholia,K. U. Natarajan,A. Mishra,K. K. Singh +44 more
TL;DR: These Lipid Association of India (LAI) recommendations refer to specific patient populations, including patients with heart failure, chronic kidney disease, non-alcoholic fatty liver disease, cerebrovascular disease, thyroid disorders, inflammatory joint diseases, familial hypercholesterolaemia and human immunodeficiency virus infection.
29
Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in western India
A. Sajgure,Ajit Vamanrao Kulkarni,Atul M Joshi,Vasanti Sajgure,Vaishali Pathak,R. P. Melinkeri,Shilpa Pathak,S. Agarwal,Manoj Naik,M. G. Rajurkar,Ameya Sajgure,Girish Date +11 more
TL;DR: In this article , a prospective non-randomised open label study with the objective to assess the effect of addition of mycophenolate to the standard of care on mortality due to COVID-19 and duration of hospital stay was conducted.
12
Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV
Raman Puri,Manish Bansal,Vimal Mehta,P. Barton Duell,N. D. Wong,SS Iyengar,Dinesh Kalra,Devaki R. Nair,Navin C. Nanda,Jagat Narula,P. Deedwania,Jamal Yusuf,Jamshed J Dalal,Sadanand Shetty,Vinod M Vijan,R Agarwala,Soumitra Kumar,Kris Vijay,Aziz Khan,Gurpreet Singh Wander,PC Manoria,SK Wangnoo,Viswanathan Mohan,Shashank R Joshi,Balbir Singh,Prafulla Kerkar,Rajesh Rajput,D Prabhakar,Abdul Hamid Zargar†,Banshi Saboo,Ravi R Kasliwal,Saumitra Ray,Sandeep Bansal,MU Rabbani,Shibba Takkar Chhabra,Sarat Chandra,Neil Bardoloi,Narasaraju Kavalipati,Immaneni Sathyamurthy,Kunal Mahajan,Akshya Pradhan,NN Khanna,Rajesh Khadgawat,PR Gupta,M. Chag,Ashu Gupta,A. Murugnathan,SN Narasingan,Sundeep Upadhyaya,V Simon Mittal,R. P. Melinkeri,Madhur Yadav,M. R. Mubarak,KK Pareek,Pradeep Kumar Dabla,Rashmi Nanda,Jc Mohan +56 more
TL;DR: The Lipid Association of India updates its 2016 cardiovascular risk assessment algorithm and treatment goals, emphasizing lifetime risk, early aggressive prevention, and statin therapy for high-risk individuals with subclinical atherosclerosis in Indians.
9
Hunting for homozygous FH - lessons learnt
S. Sitharama Iyengar,Lai,Rashmi Sudha Puri,P. Gupta,R. P. Melinkeri,S N Narasingan,Aisaku Pradhan,P. Jain,A. Mehta,M. Chag,H. Basavanagowda,D Prabhakar,A. S. Dileep +12 more
TL;DR: In this paper , the Lipid Association of India planned to collect cases of homozygous familial hypercholesterolemia (HoFH) and in the process, to identify lacunae that linger in the field.
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India.
Raman Puri,Vimal Mehta,P. Barton Duell,S. Sitharama Iyengar,Jamal Yusuf,Jamshad Dalal,S N Narasingan,Dinesh Kalra,Aditya Kapoor,Akshyaya Pradhan,Saibal Mukhopadhyay,Krishnaswami Vijayaraghavan,Rajeev Aggarwal,A Muruganathan,D Prabhakar,Sundeep Misra,Sadanand Shetty,Ravi R Kasliwal,Manish Bansal,Namita Khannab,Aziz Ullah Khan,R. P. Melinkeri,Soumitra Kumar,Rabindra Nath Chakraborty,Neil Bardoloi,P. K. Sahoo,Palaniappen Vinayagam,Ranjan Modi,Rashmi Nanda,Nathan D. Wong +29 more
TL;DR: In this paper , the authors proposed individualized aggressive LDL-C goals after acute coronary syndrome (ACS), which can be rapidly achieved with high intensity statin therapy and subsequent goal-directed adjunctive treatment with ezetimibe and PCSK9 inhibitors.